The controversial biohacker has detailed his latest experiment in age reversal using full plasma replacement therapy.
Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia ... be used concomitantly with intravenous immunoglobulin and plasma exchange ...
Efgartigimod efficacy and safety in refractory myasthenia gravis: UK’s first real-world experience
Background We report our experience of patients with generalised myasthenia gravis (gMG ... 54.2% of patients required regular intravenous immunoglobulin/plasma exchange. 75% of patients had a mean ...
Background Early fast-acting treatment (EFT) is the aggressive use of fast-acting therapies such as plasmapheresis, intravenous immunoglobulin and/or intravenous ... a practical therapeutic target for ...
including generalized myasthenia gravis (gMG) globally, primary immune thrombocytopenia (ITP) in Japan, and chronic inflammatory demyelinating polyneuropathy (CIDP) in the U.S., Japan, and China.
In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...
It’s show-me time for batoclimab, an antibody treatment from Immunovant and Roivant Sciences. Here's what you need to know.
For this study, outcomes were compared between 2 groups of patients with myasthenia gravis: those who developed exacerbations ...
The FDA has granted Priority Review to nipocalimab for the treatment of antibody positive patients with generalized myasthenia gravis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback